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Control of foot-and-mouth disease (FMD) in Uganda by ring vaccination largely depends on 2 
costly trivalent vaccines and use of monovalent vaccines could improve the cost effectiveness. 3 
This, however, requires application of highly specific diagnostic tests. This study investigated 4 
outbreaks of FMD in seven Ugandan districts, during 2011, using the PrioCHECK FMD-NS® 5 
ELISA, solid phase blocking ELISAs (SPBEs) and virus neutralization tests (VNTs), together 6 
with virological analyses for characterization of the responsible viruses. Two hundred and 7 
eighteen (218) cattle and 23 goat sera as well as 82 oropharyngeal fluid/epithelial tissue 8 
samples, were collected.  Some 50% of the cattle and 17% of the goat sera were positive by the 9 
PrioCHECK FMD-NS® ELISA, while SPBEs identified titres ≥80 for antibodies against 10 
serotype O FMD virus (FMDV) in 51% of the anti-NSP positive cattle sera. However, 35% of 11 
the anti-NSP positive cattle sera had SPBE titres ≥80 against multiple serotypes, primarily 12 
against serotypes O, SAT 1 and SAT 3.  13 
Comparison of SPBEs and VNTs for the detection of antibodies against serotypes O, SAT 1 14 
and SAT 3 in 72 NSP positive cattle sera showed comparable results against serotype O (P =  15 
0.181), while VNTs detected significantly fewer samples positive for antibodies against SAT 16 
1 and SAT 3 than the SPBEs (P < 0.001). Detection of antibodies against serotype O was 17 
consistent with the isolation of serotype O FMDVs from 13 samples. Four of these viruses 18 
were sequenced and belonged to two distinct lineages within the East Africa-2 (EA-2) 19 
topotype, each differing from the currently used vaccine strain (EA-1 topotype). The 20 
relationships of these lineages to other serotype O viruses in the Eastern Africa region are 21 
discussed. 22 
To enhance the control of FMD in Uganda, there is need to improve the specificity of the SAT-23 
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 2 
Introduction  3 
Foot-and-mouth disease (FMD) is a highly transmissible, acute vesicular disease of cloven-4 
hoofed animals including domesticated and wild ruminants and pigs (Alexandersen and 5 
Mowat, 2005; Grubman and Baxt, 2004). The disease is endemic in Uganda and most FMD 6 
outbreaks have been observed within cattle with severe effects on food security and household 7 
income (Ayebazibwe et al., 2010a; Rutagwenda, 2003). FMD virus (FMDV) exists in seven 8 
antigenically distinct serotypes (O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3) with different 9 
geographical distributions but causing clinically similar disease (Knowles and Samuel, 2003; 10 
Rweyemamu et al., 2008). In Uganda, recent isolates of FMDV from cattle have mostly been 11 
serotype O (Balinda et al., 2010b; Kasambula et al., 2012) but SAT 2 was also detected 12 
(Balinda et al., 2010a), while SAT 1 and SAT 2 viruses have been isolated from African 13 
buffalos (Syncerus caffer) (Ayebazibwe et al., 2010c). SAT 3 virus was last isolated (within 14 
Uganda) from African buffalos in Queen Elizabeth National Park (QENP) in 1997 (Kalema-15 
Zikusoka et al., 2005) while a serotype C strain was last identified in 1971 and Asia 1 has never 16 
been diagnosed on the African continent (Vosloo et al., 2002).  17 
Post-outbreak ring vaccination is one of the control strategies used within Uganda in the event 18 
of an outbreak (Namatovu et al., 2013). However, since vaccination against one serotype does 19 
not confer protection against other serotypes (Rweyemamu et al., 2008), there is a need for 20 
accurate serotype identification, if effective vaccines are to be selected.  21 
According to the OIE, detection of FMDV antigen or nucleic acid in epithelial and vesicular 22 
fluids using virological or molecular techniques is sufficient for positive diagnosis (OIE, 2012), 23 
since these tests are relatively sensitive, specific and can be quick (Callahan et al., 2002; Paixao 24 
et al., 2008). However, the difficulties in obtaining appropriate virus-containing material and 25 
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lack of the required biocontainment level and infrastructure has limited use of some of these 1 
techniques in FMD endemic areas (Longjam et al., 2011; OIE, 2008 ; OIE, 2012; Paixao et al., 2 
2008). Consequently, like a number of other countries, Uganda still relies on serological tests 3 
to serotype FMD outbreaks and for obtaining information for selection of vaccines (Muleme 4 
et al., 2012), since these assays are inexpensive, suitable for screening many samples, not 5 
dependent on cell cultures and only require low level biocontainment facilities (OIE, 2012). 6 
Pan-FMDV antibody ELISAs based on FMDV non-structural proteins (NSPs) have been 7 
developed and used for screening herds for the presence of antibodies against NSPs which are 8 
elicited during FMDV infection (Clavijo et al., 2004; Sorensen et al., 2005). However, these 9 
tests do not identify the serotype-specificity of the antibodies, which has to be determined using 10 
separate antibody tests for each of the seven serotypes of FMDV. Such assays include the OIE 11 
recommended liquid phase blocking ELISA (LPBE) and virus neutralization test (VNT) (OIE, 12 
2012) but also the solid phase blocking ELISA (SPBE) (Balinda et al., 2009; Have and Jensen, 13 
1983). All three tests detect antibodies against the viral structural proteins which are elicited 14 
by both vaccination and infection (OIE, 2012). The SPBE has been successfully used in 15 
Denmark, which is free from FMD, and was recently implemented on sera from Ugandan 16 
buffalos and livestock (Ayebazibwe et al., 2010b; Balinda et al., 2009; Mwiine et al., 2010b). 17 
However, the performance of the SPBE in the endemic situation has never been compared to 18 
the virus neutralization test (VNT), the OIE “gold standard”, for detection of antibodies against 19 
FMDV.  20 
The aim of this study was to evaluate the performance of the SPBEs for the identification of 21 
the serotype-specificity of antibodies generated against FMDV in an endemic situation which 22 
has repeated outbreaks and where vaccination is used. Moreover, these assays were applied in 23 
conjunction with other serological and virological assays to characterize the viruses responsible 24 




Materials and methods 2 
Study area and sampling strategy  3 
This study was conducted on outbreak samples collected from seven Ugandan districts that 4 
reported FMD outbreaks between January and April, 2011. These included: Bukedea and Kumi 5 
in Eastern region, Gomba and Sembabule in Central region, Kiruhura and Isingiro in South-6 
Western region and Rakai in Southern region (Figure 1). With the exception of farms in Gomba 7 
and Sembabule, which were fenced, the sampled herds were reared under free-range communal 8 
grazing management systems with some herds in the Southern region grazing with cattle close 9 
to, or across, the border with Tanzania.  10 
The districts were purposively selected based on reported FMD outbreaks and the in-charge 11 
veterinary officer offered guidance about the affected herds. Samples were collected mainly 12 
from cattle herds (local breeds) which showed overt clinical signs but, when present, also from 13 
a few apparently healthy goats grazing with the affected cattle. Bukedea, Gomba and Kumi 14 
districts had not vaccinated against FMDV for at least 10 years and the herd Kr.1 from Kiruhura 15 
district had not vaccinated for 3 years, while the vaccination status was unknown for Rakai and 16 
Sembabule. In contrast, Isingiro district had vaccinated within the 8 months before the 17 
sampling (Table 2). Additionally, samples were taken from one healthy Friesian cross-breed 18 
herd (Kr.2) in Kiruhura district that had last experienced an outbreak of FMD in 1991 but had 19 
vaccinated their animals shortly before the sampling. When vaccination had been performed, 20 
a trivalent, non-purified vaccine including FMDV serotypes O, SAT 1 and SAT 2 had been 21 
used. 22 
Sampling and sample preparation 23 
The animals were clinically examined for oral and hoof lesions, with consent of the farmers, 24 
and samples were collected including blood, oral epithelial tissues and oro-pharyngeal fluids 25 
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(OPs) from affected cattle, while blood was collected from goats. Altogether, 218 blood, 2 1 
tissue and 80 OP samples were collected from cattle, and 23 blood samples were collected from 2 
goats. In Gomba, only blood samples were obtained.  3 
Farmers were interviewed about the age of their animals, animal management system, 4 
suspected source of outbreak, previous outbreaks and vaccination including, if applicable, the 5 
type of vaccine used. In addition, the in-charge veterinary officers were interviewed about the 6 
history of outbreaks and vaccination, the vaccine used and the instituted control measures. 7 
Sera were prepared from blood samples in the field using a Mobilespin 12V field centrifuge 8 
(Mobilespin, Vulcon Technologies, Gransview, MO, USA) and kept on ice until stored at  9 
-20°C in the laboratory. The OP fluids were preserved in phosphate-buffered saline (PBS) 10 
while epithelial tissues were preserved using 50% PBS and 50% glycerol, and both were stored 11 
in liquid nitrogen during transit to the laboratory where they were stored at -80°C.   12 
Laboratory methods 13 
Screening for antibodies against FMDV non-structural proteins (NSPs) 14 
Sera were screened for antibodies against NSPs using the PrioCHECK® FMDV NS kit 15 
(Prionics® AG, Zurich, Switzerland), as developed by Sorensen et al. (1998), according to the 16 
manufacturer’s instructions except that optical density (OD) values were measured at dual 17 
wavelengths of 450 nm and 620 nm using a Multiskan Ascent spectrophotometer (Thermo 18 
Labsystems Oy, Helsinki, Finland). Results were expressed as percentage inhibition (PI) 19 
relative to the mean of the negative controls; PI=100-((OD of test sample (OD450 - OD620)/OD 20 
of mean negative control (OD450 - OD620)) ×100). Sera with PI ≥50% were considered positive. 21 
Determination of serotype-specificity of antibodies against FMDV using SPBEs Serotype-22 
specific antibodies, in the samples positive in the Priocheck® FMDV NS test, were detected 23 
using serotype-specific SPBEs as described by Balinda et al. (2009). Samples were screened 24 
at a dilution of 1:10 in each of the seven SPBEs. The optical density (OD) values were 25 
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measured as described for the PrioCHECK® FMDV NS test and ODs were converted into 1 
optical density percentage (ODP) values using the formula; ODP = (OD of test sample (OD450 2 
- OD620)/OD of mean negative control (OD450 - OD620)) × 100. The samples were considered 3 
positive when the ODP values were ≤50% for serotypes O, SAT 1, SAT 2 and SAT 3, ≤45% 4 
for serotype A and ≤35% for serotypes C and Asia 1 (Balinda et al., 2009). 5 
All positive sera were titrated using two-fold dilutions from 1:10 to 1:1280 in the relevant 6 
SPBEs and titres were expressed as the reciprocal of the highest positive dilution. In this study, 7 
the cut-off was set at a titre ≥80 being positive for all serotypes.  8 
Detection of serotype-specific antibodies against FMDV using VNT  9 
The few samples with titres ≥80 in the SPBEs for antibodies against A, C, Asia 1 and SAT 2 10 
were tested in VNT. In addition, the 72 samples positive in the NSP-ELISA that were available 11 
in adequate amounts were analysed using the VNT for antibodies against O, SAT 1 and SAT 12 
3 to compare with the SPBE results. The protocol was adapted from the procedure described 13 
in the OIE terrestrial manual (OIE, 2012). Briefly, on the test plate, sera were two-fold diluted 14 
in quadruplicate from 1:10 to 1:1280. Virus strains used were: O Manisa, A Iraq 24/64, C 15 
Noville, Asia 1 IND 8/79, SAT 1 BOT/68, SAT 2 ZIM 5/81 and SAT 3 ZIM 4/81. Controls 16 
included cell control, 10-fold titration of the virus (10-3-100) and titration of a positive standard 17 
serum. To all wells, except for the cell controls and virus control, 100 TCID50 of FMDV (in 18 
50 µl) was added to an equal volume of diluted serum and incubated at 37°C for 1 hour, 19 
followed by addition of 50 μl of swine kidney (SK) cell suspension (200,000 cells/ml + 20% 20 
FCS) to all wells, and subsequent incubation at 37°C for 3 days. The plate wells were read for 21 
cytopathic effect (CPE) under the microscope and 50% end-point titres calculated according to 22 
Reed and Muench, (1938). A titre ≥45 was considered positive, while 16-44 was considered 23 
doubtful and <16 negative.  24 
Detection of FMDV by virus isolation (VI) 25 
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The preparation of epithelial tissues and procedure for virus isolation were adapted from the 1 
method described in the OIE terrestrial manual (OIE, 2012) essentially as in Ayebazibwe et al. 2 
(2010c). Briefly, the samples (OPs or 10% suspension of epithelial tissues in Eagles media) 3 
were diluted 1:2 and 1:4, and each dilution was added to 5 wells of 96 well tissue culture plates 4 
with monolayers of primary bovine thyroid (BTY) cells. Test samples were separated by wells 5 
with uninfected cells that served as negative control and the plates were incubated for two hours 6 
at 37oC (with CO2). Thereafter all wells containing samples were washed using Eagles media 7 
with 2% FCS and 150μl/well of the same media was added and further incubated for 1-2 days 8 
as above. The plates were examined for CPE every 24 hours and CPE-positive samples were 9 
frozen for harvesting, while those without CPE after 48 hours were harvested by freeze-10 
thawing and subjected to another passage on BTY monolayers as described above. Samples 11 
which showed no CPE following two passages were considered negative. 12 
Verification of FMDV in CPE-positive samples and identification of FMDV serotype by 13 
antigen ELISA (Ag ELISA) 14 
The presence of FMDV in CPE-positive harvests was investigated using an in-house serotype-15 
specific antigen ELISA based on the description by OIE (2012) as described by Ayebazibwe 16 
et al. (2010c). Briefly, the same reagents as in the SPBE were used, but the rabbit hyperimmune 17 
sera for all seven serotypes were each coated in one row of the same plate and the samples 18 
were then added in duplicate to all seven rows. Moreover, the serotype-specific positive 19 
controls (strong and weak) and negative cell culture controls were added in single wells in the 20 
relevant rows. Positive reactions were identified using the serotype-specific guinea pig antisera 21 
and results were interpreted after subtracting the OD-value of the negative control wells from 22 
that of the samples. Any sample with an OD-difference of >0.2 was considered positive, while 23 
values between 0.1 and 0.2 were inconclusive.  24 
FMDV RNA extraction and diagnostic quantitative RT-PCR (qRT-PCR) 25 
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RNA was extracted from CPE positive cell culture supernatant using the Viral RNA Mini Spin 1 
Protocol in the QIAamp® Viral RNA Mini Kit (Qiagen, GmbH, Hamburg, Germany) following 2 
the manufacturer’s instruction. cDNA for the qRT-PCR was synthesized using the TaqMan kit 3 
(Perkin Elmer (PE) Biosystems) by adding 9 µl of Master mix (1.5 µl of 10 × TaqMan RT-4 
buffer, 3.3 µl of 25 mM MgCl2, 3.0 µl of dNTP (2.5mM each)), 0.5 µl of 50 µM Random 5 
hexamers, 0.3 µl of RNase inhibitor (20U/µl), 0.375 µl of MultiScribe reverse transcriptase 6 
(100U/µl Moloney RT) and 6 µl of RNA per tube. The tubes were transferred to a heating 7 
block and incubated at 48˚C for 45 min followed by 95˚C for 5 min. The qRT-PCR was 8 
performed using primers and probes as described previously (Reid et al., 2002). 9 
Sequencing of FMDV VP1 coding region 10 
The cDNA for sequencing was synthesized using Ready-To-GoTM You-Prime First-strand 11 
Beads (GE Healthcare Life Sciences, Uppsala, Sweden) using pdN6 Random 12 
Hexamers (50ng/µl). The PCR products corresponding to the VP1-coding region for 13 
sequencing were prepared as described in Balinda et al. (2010b) using reactions of 50 μl volume 14 
containing: 25.1 μl of water, 5 μl 10× AmpliTaq Gold buffer, 4 μl MgCl2 (25 mM), 0.4 μl 15 
dNTPs (2.5 mM each), 0.5 μl of Amplitaq Gold® DNA polymerase (Applied Biosystems, Life 16 
Technologies ), 5 μl of template cDNA and 5 μl of the forward (11-FPN 29: 5’-3’ 17 
GCIGCIGACTACGCITACACYGC, where I= inosine and Y= C or T) and reverse (11-FPN 18 
28: 5’-3’ GGGCCCAGGGTTGGACTC) primers, both at a concentration of 5 pmol/μl as used 19 
by Wekesa et al. (2013). 20 
The PCR products were analysed on gels using 1.5 % Seakem GTG agarose in 1 X TAE (low 21 
EDTA) buffer with a marker (ФX 174 HaeIII digest) (Fisher Scientific, Slangerup, Denmark). 22 
Electrophoresis was performed using 120 volts for 1 hour and the gel was stained in 250 mls 23 
of water containing 40 μl of 1% w/v ethidium bromide for 30 minutes on a shaking table. Gel 24 
purification of the amplicons was performed using the Qiaquick® gel extraction kit (Qiagen, 25 
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GmbH, Hamburg, Germany) and Cycle sequencing was performed with 1-50 ng of PCR 1 
product using the Big dye® terminator v3.1 cycle sequencing kit (Applied Biosystems) and an 2 
ABI PRISM® 3700 automated DNA sequencer (Applied Biosystems).  3 
Data analysis 4 
The differences between the seroprevalence values obtained with SPBEs and VNT for 5 
antibodies against serotypes O, SAT 1 and SAT 3 were analysed using the McNemar test 6 
(Motulsky, 1995).  7 
Base calling of nucleotide sequences was done using seqMan Pro software (DNAstar, Inc., 8 
Madison, USA). Sequences from older East African isolates which are related to the study 9 
sequences were obtained using BLAST searches from NCBI (http://www.ncbi.nlm.nih.gov/). 10 
The sequences analysed correspond to the VP1 coding region and details of the new and related 11 
sequences are summarised in Table 1. Multiple sequences were aligned using Muscle (codons) 12 
(Edgar, 2004) incorporated in MEGA 5 (Tamura et al., 2011). A phylogenetic tree of these 13 
sequences was estimated using the Neighbor-Joining method (Saitou and Nei, 1987). The 14 
percentage of replicate trees in which the associated taxa clustered together in the bootstrap 15 
test (2000 replicates) is shown next to the branches (Felsenstein, 1985). The tree is drawn to 16 
scale with branch lengths in the same units as those of the evolutionary distances used to infer 17 
the phylogenetic tree. The evolutionary distances were computed using the Tamura 3-18 
parameter method (Tamura, 1992) and are in the units of the number of base substitutions per 19 
site. The rate variation among sites was modeled with a gamma distribution (shape parameter 20 
= 1). The analysis involved 18 nucleotide sequences and codon positions included were 21 
1st+2nd+3rd. All positions containing gaps and missing data were eliminated. There were a total 22 
of 636 positions in the final dataset. Evolutionary analyses were conducted in MEGA 5 23 
(Tamura et al., 2011).  24 
Ethical approval 25 
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This research is part of a larger on-going strategic project ‘Transboundary Animal Diseases in 1 
East Africa’. Ethical approval for the project was kindly granted by the Ministry of Agriculture 2 
Animal Industry and Fisheries, Uganda. 3 
 4 
Results 5 
Screening for antibodies against FMDV using PrioCHECK® FMDV NS ELISA 6 
One hundred and nine out of 218 (50%) cattle sera and four out of 23 (17%) goat sera collected 7 
from premises with suspected FMD had antibodies against NSPs with herd prevalences ranging 8 
from 13% to 100% in cattle and from 0% to 33% in goats (Table 2).  9 
Serotyping of antibodies against FMDV using SPBEs 10 
All samples positive in the PrioCHECK® FMDV NS assay were screened in the seven SPBEs 11 
and positive sera were titrated when possible, however, due to insufficient amounts of serum, 12 
titration could not be carried out for a few positive samples (4-12  samples depending on the 13 
SPBE) (Table 2). After titration in SPBEs, serotype-specific antibody titres ≥80  against 14 
serotypes O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3 were identified in 51%, 7%, 3%, 1%, 15 
38%, 10% and 24%, respectively, of the 97-105 sera that could be tested in the respective 16 
SPBEs (Table 2). Forty four of the 107 anti-NSP positive samples run on SPBEs (41%) did 17 
not have antibody titres ≥80 in any of the SPBEs, while high antibody titres against a single 18 
serotype were found in 25 (23%) and against more than one serotype in 38 (36%) of the 19 
samples. The majority of the samples positive for only one serotype had antibodies against 20 
serotype O (19/25), while others had antibodies against serotypes A (2), SAT 1 (3) and SAT 21 
3 (1) (data not shown). The 38 samples with high titres against more than one serotype came 22 
from infected herds in all districts and were more frequent in districts with higher 23 
seroprevalences for antibodies against NSP, but also from the vaccinated, non-infected herd 24 
Kr.2 (Table 2). The majority (30) had antibodies against serotype O in combination with 25 
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antibodies against SAT 1 only (13), against SAT 1/other serotypes (13) or against SAT 1 
3/other serotypes (4) (data not shown). In 23 of these 30 samples, titres against serotype O 2 
were higher than or equal to titres against other serotypes, while titres against SAT 1 were 3 
highest in the remaining seven sera (data not shown). Eight samples only had high titres 4 
against the SAT serotypes, either against SAT 1 and SAT 3 (6) or against SAT 1 and SAT 2 5 
(2). 6 
In goats, evidence of exposure to FMDV as determined by SPBE was only found in one goat 7 
from Gomba that had an antibody titre of 1280 against O and 160 against SAT 1 (Table 2). 8 
Determination of serotype-specific antibodies using VNT  9 
For the sera containing antibodies against SAT 2, eight of the ten samples with titres ≥80 in 10 
SPBE were analysed in the VNT, and six of these were confirmed positive; two of the positive 11 
samples came from the uninfected but vaccinated herd (Kr.2) with SAT 2 neutralizing antibody 12 
titres of 57 and 80 in combination with low and high neutralizing titres against SAT 1 or O, 13 
respectively. The remaining four sera came from one farm in Rakai and had titres ranging from 14 
57 to 160 against SAT 2, but with higher or comparable neutralizing titres against serotype O. 15 
Moreover, SPBE antibody titres ≥80 against serotypes A, C and Asia 1 in seven, three and one 16 
sera, respectively, were not confirmed in VNT (data not shown).  17 
The comparison of the test performance for SPBEs and VNT for serotypes O, SAT 1 and SAT 18 
3 on 72/109 (66%) anti-NSP positive samples is summarized in Table 3. Thirty nine of the 72 19 
samples (54%) showed evidence of antibodies against O by both tests, while for each of SAT 20 
1 and SAT 3 only one sample (1.4%) was positive in both assays. The sample positive by VNT 21 
for antibodies against SAT 1 also had neutralizing antibodies against O but with a higher titre 22 
against SAT 1 (538 and 190, respectively) and was from the recently vaccinated herd (Kr.2), 23 
while the single serum positive for antibodies against SAT 3 had a higher titre against O (64 24 
and 226, respectively) and was from Kumi district which last vaccinated their animals more 25 
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than 10 years back. The VNT detected slightly more samples positive (49/72) for antibodies 1 
against serotype O as compared to the SPBE-O (43/72) but the difference was not statistically 2 
significant (P = 0.181). In contrast, the VNT test detected significantly fewer samples positive 3 
for antibodies against serotypes SAT 1 (1/72) and SAT 3 (1/72) as compared to SPBE for SAT 4 
1 (33/72) and SAT 3 (22/72) (P < 0.001 for both).   5 
Virus characterization by VI, Ag ELISA, RT-PCR and Sequencing  6 
Nineteen OPs out of the 82 OP/epithelial tissue samples used for virus isolation (23%) 7 
produced CPE directly in primary BTY cells or after the second passage; these were from 8 
Bukedea (one), Kumi (eight), Rakai (one) and Sembabule (nine) districts. None of the samples 9 
from Isingiro (15/82) and Kiruhura (19/82) were positive by VI (data not shown). Thirteen out 10 
of the 19 CPE containing cell culture harvests were positive on Ag ELISA and  were identified 11 
as serotype O; moreover, nine of these were also positive with lower ODs in SAT 3 Ag ELISA 12 
(data not shown).  13 
Using qRT-PCR assays, nine of the 19 CPE containing cell culture harvests had Ct-values < 14 
27, one of the selection criteria for samples for sequencing. The four samples selected for 15 
sequencing had Ct values within the range of 17 to 27, were positive for serotype O and SAT 16 
3 using Ag ELISA although with greater ODs for O than SAT 3, and these included an isolate 17 
from each of the four districts Bukedea, Kumi, Rakai and Sembabule. Testing the selected 18 
samples by conventional PCR, using two primer sets designed to target primarily either the 19 
SAT-serotypes of FMDV or serotypes O, A, C and Asia 1 of FMDV, yielded products only 20 
with the latter. The VP1 coding sequences (639 nt length) were determined and when compared 21 
with other sequences from NCBI, Genbank, using Blast, each of them were most closely 22 
matched with serotype O FMDVs (Table 1), thus confirming that serotype O was responsible 23 
for the outbreaks in these districts.  24 
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Assessment of phylogenetic relationships with older, topotype-defined, serotype O isolates 1 
from East Africa (Table 1) showed that all four strains were grouped with known strains 2 
belonging to the topotype EA-2 (Figure 2). The predicted amino acid sequences for the VP1s 3 
derived from the nucleotide sequences are shown in Figure 3. The sequences of the virus 4 
isolates U07/11and U24/11 from Rakai and Sembabule, respectively, were closely related to 5 
each other (pairwise amino acid identity of 99% and nucleotide identity of 99.5%), while the 6 
isolates U04/11 and U19/11 from Bukedea and Kumi, respectively, were identical within the 7 
VP1 coding sequence. However, the two sets of sequences from Eastern (Bukedea and Kumi) 8 
and Southern (Rakai and Sembabule) Uganda were quite distinct from each other (pairwise 9 
amino acid identity of 93%) with 71/639 (11%) nucleotide differences. Hence, these viruses 10 
belong to two different lineages within the EA-2 topotype based on a cut off of >7.5% 11 
nucleotide difference for separating lineages and <15% difference among topotypes in the VP1 12 
coding region of FMDV RNA (Samuel and Knowles, 2001; Vosloo et al., 1992). The U04/11 13 
and U19/11 viruses were each very closely related to a FMDV isolate (K251/2010) from 14 
Kwanza, Western Kenya (Wekesa et al., 2013)  with nucleotide identity of 634/639 (99%), 15 
while both the U07/11 and U24/11 isolates were closely related to the U18/06 virus from Mpigi 16 
district, Uganda with nucleotide identities of 96%. 17 
 One hundred and thirty six (21%) variable sites between the 2011 outbreak sequences and the 18 
vaccine strain in use (O/K77/78, which is topotype EA-1), were determined across the 639 19 
nucleotides which encode substitutions of 27/213 amino acids (13%). The U07/11 and U24/11 20 
viruses had pairwise amino acid identity of 90% (83% nucleotide identity) with the vaccine 21 
strain while the U04/11 and U19/11 viruses each had pairwise amino acid identity of 92% (84% 22 
nucleotide identity) with the vaccine strain. Similarly, the K251/2010 isolate (Wekesa et al., 23 
2013) had pairwise amino acid identity of 91% (84% nucleotide identity) with the vaccine 24 
strain.  25 
14 
 
Pairwise comparison of the 2011 outbreak sequences with the vaccine strain showed 18 (8.5%) 1 
amino acid variations in the U04/11 and U19/11 viruses and 23 amino acid variations (10.8%) 2 
in the U07/11 and U24/11 isolates. Most amino acid variations were noted between amino acid 3 
residues 133 to 141 which is part of the GH-loop and a key antigenic site (Aggarwal  and 4 
Barnett, 2002 ). However, the RGD motif (residues 145-147) within these viruses was 5 
conserved and so was the flanking region of the RGD motif as far as the -3 position. 6 
Conservation was also observed as far as +4 in all the viruses except for the U07/11 sequence 7 
with Alanine (A) instead of Valine (V) at +3 (amino acid residue 150) which is adjacent to 8 
residue 149, a critical component of antigenic site 5 (Crowther et al., 1993) within VP1. In the 9 
U24/11 sequence, there was also variation from Alanine (A) to Valine (V) at residue 152 which 10 
is close to 154, a critical residue within antigenic site 1 within VP1 (Kitson et al., 1990). In 11 
addition, Threonine (T) was replaced by Glutamine (Q) within the U04/11 and U19/11 viruses 12 
at residue 43, which is a critical residue within antigenic site 3 (Figure 3).  13 
 14 
Discussion 15 
The presence of antibodies against FMDV NSPs in cattle sera collected from herds with clinical 16 
signs of FMD strongly supported the clinical diagnosis. Moreover, the 60-90% prevalence of 17 
antibodies against FMDV NSPs in unvaccinated herds from Bukedea, Isingiro, Kumi and 18 
Rakai districts indicates that the sampling took place after considerable spread of the infection 19 
within the herds, while the lower seroprevalence consistently observed in herds from Gomba 20 
(29%) and Sembabule (24%) districts, as well as in the non-vaccinated herd in Kiruhura (45%), 21 
accords with sampling in an earlier phase of the outbreak (Sorensen et al., 1998). The very high 22 
prevalence of anti-NSP antibodies in herd Kr.2 in Kiruhura district, which last had an outbreak 23 
in 1991 but where the cattle are vaccinated on a yearly basis, may be attributed to repeated use 24 
of non-purified vaccines (Ayebazibwe et al., 2012; Sutmoller et al., 2003). 25 
15 
 
The seroprevalences of antibodies against FMDV NSPs found in this study are comparable to 1 
the levels found in Southern Ugandan cattle in a 2006 post FMD outbreak sampling (Mwiine 2 
et al., 2010b). In goats, the overall prevalence for antibodies against FMDV was 17%, which 3 
is lower than reported from a 2006 post outbreak sampling in Kasese and Mbarara districts, but 4 
comparable to a 2007 random sampling of goats in Kasese district (Balinda et al., 2009).   5 
The serological investigations into the FMDV serotype involved in the outbreaks using SPBEs 6 
gave a complex picture since 36% of the samples had antibody titres above the cut off level for 7 
more than one serotype, however, antibody titres were generally higher against O and SAT 1, 8 
followed by SAT 3, while titres against serotypes A, C, Asia 1 and SAT 2 were equal to or 9 
lower than at least one other serotype in all samples. Thus, based on the SPBEs, it was difficult 10 
to conclude whether serotype O or SAT 1 was responsible for the outbreak, however, the VNTs 11 
gave a much simpler picture since they predominantly identified neutralizing antibodies against 12 
serotype O. Furthermore, only serotype O FMDVs were isolated from OP fluids collected in 13 
some of the districts involved in the 2011 outbreaks which confirmed that the outbreaks were 14 
caused by serotype O FMDV.  15 
In herd Kr.2 that had been vaccinated shortly before sampling, the high simultaneous antibody 16 
titres against serotypes O, SAT 1 and SAT 2 are probably due to vaccination with the trivalent 17 
vaccines (O, SAT 1 and SAT 2) that are used in Uganda.  18 
The absence of serotype-specific neutralizing antibodies (as determined by VNT) in the few 19 
samples which were positive in SPBEs for antibodies against serotypes A, C and Asia 1, and 20 
in the vast majority of samples positive in the  SAT 1 and SAT 3 SPBEs point to cross reactions 21 
between serotypes, which are not uncommon with SPBEs (Ayebazibwe et al., 2010b; 22 
Ayebazibwe et al., 2010c; Balinda et al., 2009; Mwiine et al., 2010a; Mwiine et al., 2010b; 23 
Mwiine et al., 2010c) and the OIE recommended antibody ELISAs (Hamblin et al., 1986a; 24 
Hamblin et al., 1986b; Mackay et al., 2001) and to a lesser extent with the VNT (Hamblin et 25 
16 
 
al., 1986a; Hedger et al., 1982). According to Hamblin et al. (1986a), these cross-reactions are 1 
likely a reflection of some antigenic relationship between these virus serotypes, however, for 2 
regularly vaccinated herds, they could also be due to repeated vaccination which complicates 3 
the serological picture in endemic situations (Mwiine et al., 2010a). Moreover, the higher levels 4 
of antibodies against serotypes other than O, as found in a few samples in the SPBEs, could 5 
also be due to heterotypic responses to the causative virus caused by priming effects from past 6 
exposures (Hedger et al., 1982).   7 
The specificity performance of the SAT serotype SPBEs seemed particularly poor in this study. 8 
Since it has been previously shown that the antibody response measured by SPBE is very 9 
diverse in both vaccinated and unvaccinated infected animals for 2-3 weeks after infection 10 
(Tjørnehøj, K., unpublished data), it is expected that the SPBEs may perform better if used 11 
later than 4 weeks after infection as was observed in a post outbreak study of the Ugandan 2006 12 
FMD outbreaks (Mwiine et al., 2010b).  13 
With regard to antibodies against SAT 3, the relatively large number of samples that were 14 
positive in the SAT 3 SPBE but negative in the corresponding VNT is of particular concern, 15 
because this serotype has only been isolated from Ugandan buffalos in 1997 (Kalema-Zikusoka 16 
et al., 2005) and has never been isolated from Ugandan cattle, moreover, this serotype is not 17 
part of the employed vaccines. Thus, our results support the suspicion that the anti-SAT 3 SPBE 18 
is very unspecific and gives strong cross-reactions with antibodies against other FMDV 19 
serotypes (Tjørnehøj, K., unpublished data).  20 
To avoid the diagnostic issues of cross reactivity due to repeated vaccination, Balinda et al. 21 
(2009) and Mwiine et al. (2010a) recommended use of samples from unvaccinated species, like 22 
small ruminants, indeed, in the current study a single goat had high antibody titres  against 23 
serotype O and had a lower titre towards SAT 1, which accords with the findings in cattle in 24 
these outbreaks.  25 
17 
 
The Ag ELISA identified 13 culture harvests from OPs collected from districts of Bukedea, 1 
Kumi, Sembabule and Rakai positive for serotype O virus and indeed serotype O FMDV 2 
isolates were confirmed by sequencing four of these samples (one selected per district) 3 
indicating the presence of either acute or persistent infection. The VP1 coding regions of these 4 
four isolates showed that all of these viruses belonged to the same EA-2 topotype which is well 5 
established in Uganda (Ayelet et al., 2009; Balinda et al., 2010b; Kasambula et al., 2012). 6 
Bukedea and Kumi districts are situated next to each other in the Eastern region of Uganda, 7 
while Rakai and Sembabule are neighbouring districts in the Southern region, and not 8 
surprisingly, this was reflected in the genetic clusters with pairwise amino acid identities of 9 
100% (Bukedea and Kumi) and 99% (Rakai and Sembabule), which indicates local inter-10 
district livestock transmission which could be due to belated reporting of FMD outbreaks or to 11 
ineffective implementation of quarantine. The <5% nucleotide difference in the viruses from 12 
the Southern region indicates that they belong to the same lineage, as did the viruses from 13 
Eastern Uganda and Western Kenya, while the extent of nucleotide difference between the two 14 
pairs of Ugandan viruses (11%) showed that these were two different lineages (Samuel and 15 
Knowles, 2001; Vosloo et al., 1992), which implies circulation of more than one serotype O 16 
FMDV lineage during the 2011 outbreaks. The occurrence of related viruses in Eastern 17 
(Bukedea and Kumi) Uganda and in Western Kenya (99% nucleotide identity) provides further 18 
evidence for transboundary mobility of FMDV which may be attributed to uncontrolled cross 19 
border movements as suggested previously by Balinda et al., (2010b). 20 
The serotype O vaccine strain incorporated in the trivalent vaccines used in Uganda belongs to 21 
topotype EA-1 and it is not surprising that nucleotide difference of 16-17% and a number of 22 
amino acid substitutions separate the identified EA-2 topotype viruses from the vaccine strain. 23 
Some of these changes occur at critical antigenic sites (Figure 3) highlighting a need for vaccine 24 
18 
 
matching studies to establish the level of protection conferred by the current vaccine against 1 
the currently circulating virus strains.  2 
In conclusion, the presence of antibodies against FMDV NSPs in samples from unvaccinated 3 
herds with recent disease confirmed FMDV infection. Further serological investigations, using 4 
SPBEs and VNTs, identified antibodies against serotype O, however, there were a conspicuous 5 
number of cross-reactions in the SPBEs for antibodies against serotypes SAT 1 and SAT 3. 6 
These results accorded with the isolation of four serotype O FMDVs, which, in contrast to the 7 
topotype EA-1 vaccine strain, all belonged to topotype EA-2. The Ugandan isolates grouped 8 
into a Southern Ugandan lineage and an Eastern Ugandan lineage, of which the latter was 9 
closely related to a Western Kenyan isolate. The findings of this study highlight the challenges 10 
involved in the diagnosis and control of FMD in endemic areas and emphasize the need to: (i) 11 
improve the serotype-specificity of the existing SAT-SPBEs if they are to be used to give useful 12 
information for cost effective vaccine selection, (ii) perform vaccine matching to establish the 13 
level of protection conferred by existing vaccines against the currently circulating strains and 14 
(iii) implement regional FMD control measures. 15 
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Figure legends 10 
  11 
Figure 1. The  study area.  12 
The map shows the seven districts of Uganda that reported FMD outbreaks between January 13 
and April, 2011. These districts included; Bukedea and Kumi from the Eastern region, Gomba 14 
and Sembabule from the Central region, Isingiro and Kiruhura from the South- Western region 15 
and Rakai from the Southern region. 16 
 17 
Figure 2. Neighbour–Joining Phylogeny tree based on VP1 coding sequences showing the 18 
relationship between Ugandan 2011 serotype O and earlier East African serotype O 19 
viruses. The four 2011 Ugandan and one 2010 Kenyan outbreak FMDV sequences are marked 20 
with asterisks (*) and O/K77/78** is the serotype O virus strain incorporated in the trivalent 21 
vaccines (O, SAT 1 and SAT 2) used in Uganda. Bootstrap values larger than 50% are depicted 22 
in the tree. 23 
 24 
Figure 3. Alignment of sixteen inferred amino acid sequences of the VP1 region from the 25 
2011 outbreak (marked with an asterisk (*)) and earlier East African serotype O strains. 26 
The dots show identity with the consensus sequence O/K77/78** (the vaccine strain). Similar 27 
amino acid variations exist between the isolates U04/11 (Bukedea) and U19/11 (Kumi) while 28 
27 
 
the U07/11 (Rakai) and U24/11 (Sembabule) viruses had unique differences within the region 1 
150-153. The sequence of K251/2010 (Kwanza, Kenya) (Wekesa et al., 2013) differed from 2 




Table legends 7 
Table 1. East African FMDV serotype O sequences used for comparison in this study 8 
*: the recent 2011 Ugandan and 2010 Kenyan FMDV outbreak sequences included in this study 9 
and **: the FMDV strain incorporated in the trivalent vaccine currently used in Uganda.  10 
 11 
Table 2. Detection of antibodies against non-structural and structural proteins of FMDV 12 
a: last vaccination in 1989 and last outbreak more than 10 years back; b: no vaccination done; c: 13 
last vaccination in July/2010 and last outbreak in September/2009; d: Kr.2 herd vaccinated on 14 
annual basis (most recently in March/2010) and last outbreak in1991; e: last vaccination more 15 
than 10 years back; f: no information on last vaccination and g: vaccination status unknown  16 
 17 
Table 3. Comparative evaluation of SPBE and VNT assays for the detection of antibodies 18 
against structural proteins of FMDV in cattle in seven Ugandan districts with reported 19 
FMD outbreaks in 2011 20 









Table 1. East African FMDV serotype O sequences used for comparison in this study 
Reference Number Date of 
collection 





U04/11*  04/3/2011 Bukedea, Uganda KF478938 EA-2 this study 
U19/11*  04/3/2011 Kumi, Uganda KF478940 EA-2 this study 
U24/11* 09/3/2011 Sembabule, 
Uganda 
KF478941 EA-2 this study 
U07/11*  01/4/2011 Rakai, Uganda KF478939 EA-2 this study 
K251/2010* 29/12/201
0 
Kwanza, Kenya KF207887 EA-2 (Wekesa et al., 2013)  
OUGA2009 Lira 2009 Lira, Uganda JN974308 EA-2 (Kasambula et al., 2012) 
OUGA2008 
Kamuli 
2008 Kamuli, Uganda JN974312 EA-2 (Kasambula et al., 2012) 
U18/06 2006 Mpigi, Uganda HM75662
7 
EA-2 (Balinda et al., 2010b) 
K147/00 2000 Trans Nzoia, Kenya HM75661
2 
EA-2 (Balinda et al., 2010b) 
U97/99 1999 Uganda HM75660
4 
EA-4 (Balinda et al., 2010b) 
K121/91 1991 Kiambu, Kenya HM75659
5 
EA-1 (Balinda et al., 2010b) 
O/UGA/17/98 1998 Uganda HM21107
5 
EA-4 (Ayelet et al., 2009)  
K114/87 1987 Kiambu, Kenya HM75659
4 
EA-3 (Balinda et al., 2010b) 
K11/84 1984 Kiambu, Kenya HM75659
1 
EA-3 (Balinda et al., 2010b) 
K101/80 1980 Laikipia, Kenya HM75658
9 
EA-3 (Balinda et al., 2010b) 
O/K77/78** 1998 Kenya DQ16507
2  
EA-1 (Balinda et al., 2010b) 
O/UKG/15/81 
 
19/3/1981 Jersey, UK JX869193 ME-SA Wright et al.,  
(Unpublished ) 
O/UKG/16/81 21/3/1981 Isle of Wight, UK JX869194 ME-SA Wright et al.,  
(Unpublished) 
*: the recent 2011 Ugandan and 2010 Kenyan outbreak FMDV sequences included in this study 

















Positive   
Proportion of  NSP positive sera with evidence of antibodies 
against the different serotypes using SPBEs ( titre ≥80) 
O A C Asia 1 SAT 1 SAT 2 SAT 3 
1. cattle          
Bukedeaa          
           
Bk.1 
10 6 3/6 0/5 0/6 0/6 4/6 0/6 3/6 
Gombab          
Gb.1 15 3  0/3 0/3 0/3 0/3 0/3 0/3 0/3 
Gb.2 16 6 1/4 0/4 0/4 0/4 3/5 0/5 1/5 
Sub total 31 9  1/7 0/7 0/7 0/7 3/8 0/8 1/8 
Isingiroc          
         Is.1 20 18  12/16 0/16 0/15 0/17 5/18 0/17 2/16 
Kiruhurad          
Kr.1 11 5  0/4 0/4 0/4 0/4 0/4 0/4 0/4 
Kr.2 6 5  3/5 1/5 1/5 0/5 4/5 3/5 4/5 
Sub total 17 10  3/9 1/9 1/9 0/9 4/9 3/9 4/9 
Kumie          
  Km.1 3 3 0/3 0/3 0/3 0/3 2/3 0/3 2/3 
Km.2 35 21 9/21 2/21 0/21 0/21 6/20 0/21 4/17 
Sub total 38 24 9/24 2/24 0/24 0/23 8/23 0/24 6/20 
Rakaif          
Rk.1 13 13  10/11 1/11 0/13 0/11 3/12 1/13 1/13 
Rk.2 9 4  3/4 1/3 0/4 0/4 3/4 0/4 1/4 
Rk.3 11 11  8/9 2/9 2/11 1/10 8/11 6/11 6/11 
Sub total 33 28  21/24 4/23 2/28 1/25 14/27 7/28 8/28 
Sembabuleg         
Sb.1 31 4  1/3 0/3 0/3 0/3 1/3 0/3 0/3 
Sb.2 5 1  0/1 0/1 0/1 0/1 0/1 0/1 0/1 
Sb.3 21 6  0/6 0/6 0/6 0/6 0/6 0/6 0/5 
Sb.4 12 3  0/3 0/3 0/3 0/3 0/3 0/3 0/3 
Sub total 69 14  1/13 0/13 0/13 0/13 1/13 0/13 0/12 


















2. Goats          
Bukedea          
Bk.1 5 1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 
Gomba          
Gb.2 9 2  1/2 0/2 0/2 0/2 1/2 0/2 0/2 
Kumi          
Km.1 3 1  0/1 0/1 0/1 0/1 0/1 0/1 0/1 
Km.2 6 0  - - - - - - - 
Total 23 4 (17%)  1/4  0/4 0/4 0/4 1/4  0/4  0/4  
a: last vaccination in 1989 and last outbreak more than 10 years back; b: no vaccination done; c: 
last vaccination in July/2010 and last outbreak in September/2009; d: Kr.2 herd vaccinated on 
annual basis (most recently in March/2010) and last outbreak in1991; e: last vaccination more 
than 10 years back; f: no information on last vaccination and g: vaccination status unknown  
Table 3. Comparative evaluation of SPBE and VNT assays for the detection of antibodies against structural proteins of FMDV in cattle 





SPBE and VNT results for Serotypes 
O  










SAT 1 + 
 
VNT- 
SAT 1 + 
SPBE-SAT 1/VNT –







SAT 3 results 
+/+ +/- -/+ -/-   +/+ +/- -/+ -/-   +/+ +/- -/+ -/- 
Bukedea 6 3 4 3 - 1 2 4 0 - 4 - 2 3 0 - 3 - 3 
Gomba 1 1 0 - 1 - - 1 0 - 1 - - 0 0 - - - 1 
Isingiro 8 8 7 7 1 - - 3 0 - 3 - 5 1 0 -
  
1 - 7 
Kiruhura 4 3 2 2 1 - 1 4 1 1* 3 - - 4 0 - 4 - - 
Kumi 20 9 16 8 1 8 3 8 0 - 8 - 12 8 1 1* 7 - 12 
Rakai 19 18 19 18 - 1 - 12 0 - 12 - 7 6 0 - 6 - 13 
Sembabule 14 1 1 1 - - 13 1 0 - 1 - 13 0 0 - - - 14 












1  21 
 
0  50  
*: Samples also positive in VNT for antibodies against serotype O FMDV  
 
